Lorelei Fen
Nurse Practitioner · Riverdale, NJNPI 1649312893
Payments from drug & device makers
Across 45 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$199
- AstraZeneca$104
- Astellas Pharma US Inc$59
- Novartis$59
- Pfizer$56
- Bayer$46
- plus $465 from 21 others
What the payments were for
- Food & beverage$78980%
- Education$19920%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $199 |
| AstraZeneca | 6 | $104 |
| Astellas Pharma US Inc | 3 | $59 |
| Novartis | 3 | $59 |
| Pfizer | 3 | $56 |
| Bayer | 2 | $46 |
| Merck | 2 | $42 |
| Johnson & Johnson | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| GSK | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Genmab U.S., Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Legend Biotech USA Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| AbbVie | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $15 |
| Invivyd Inc | 1 | $15 |
| Seagen Inc. | 1 | $13 |
How this compares
$988 in reported general payments places this provider in the 80th percentile of 2,138 nurse practitioner providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 11 | $616,395 |
| RevlimidLenalidomide | 20 | $355,327 |
| VenclextaVenetoclax | 28 | $301,978 |
| ImbruvicaIbrutinib | 15 | $238,506 |
| BrukinsaZanubrutinib | 17 | $236,627 |
| JakafiRuxolitinib Phosphate | 15 | $231,097 |
| PromactaEltrombopag Olamine | 12 | $149,272 |
| Imatinib Mesylate | 18 | $55,940 |
| EliquisApixaban | 56 | $48,650 |
| XareltoRivaroxaban | 38 | $41,473 |
| Enoxaparin Sodium | 11 | $4,192 |
| Anastrozole | 163 | $3,961 |
| Exemestane | 20 | $1,592 |
| Letrozole | 49 | $1,046 |
| Hydroxyurea | 44 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKOjjaara | $35 | $616,39511 claims |
| Bristol Myers SquibbRevlimid | $16 | $355,32720 claims |
| AbbVieVenclexta | $16 | $301,97828 claims |
| NovartisPromacta | $59 | $149,27212 claims |
| PfizerEliquis | $56 | $48,65056 claims |
| Johnson & JohnsonXarelto | $41 | $41,47338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Riverdale
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Olufunmilayo IloriUnion$133K
- Janice BeitzHaddon Heights$75K
- Adewale AdefowojuUnion$70K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.